Log in Free sign up

Panbela Therapeutics (PBLA) News and press releases

News

From Benzinga Pro

Panbela Therapeutics: Q1 Earnings Insights

Panbela Therapeutics (NASDAQ:PBLA) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:15 PM. Here's what investors need to know about the announcement.

Panbela Therapeutics Q1 EPS $(0.27) Misses $(0.25) Estimate

Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.25) by 8 percent. This is a 17.39 percent decrease over losses of $(0.23) per share

Earnings Scheduled For May 12, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.

The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

Panbela Therapeutics Q4 EPS $(0.26) Misses $(0.18) Estimate

Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.18) by 44.44 percent. This is a 188.89 percent decrease over losses of $(0.09) per

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Earnings Scheduled For March 24, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter.

Preview: Panbela Therapeutics's Earnings

Panbela Therapeutics (NASDAQ:PBLA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts estimate that Panbela Therapeutics will report an earnings per share (EPS) of $-0.18.

The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings

Biotech, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment during the week.

Panbela Therapeutics Acquires Cancer Prevention Pharmaceuticals For Stock & Milestone Payment

Biotech, M&A, News, Penny Stocks, Health Care, Movers, Trading Ideas, General

Panbela Therapeutics Inc (NASDAQ: PBLA) has

Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.; Under Terms, Holders Of Panbela Are Expected To Own ~59% Of Post-Merger Holding Co.

Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address considerable unmet needs Combined pipeline extends from pre-clinical to registration studies,

Press releases

From Benzinga Pro

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates IIN, PBLA, TEN, REGI

Small Cap, Press Releases

NEW YORK, May 5, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sh

PANBELA THERAPEUTICS INVESTOR ALERT - Kuznicki Law PLLC Investigates Panbela Therapeutics, Inc. - PBLA

Kuznicki Law PLLC is investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela Therapeutics, Inc. ("the Company") (NasdaqCM: PBLA). Under the terms of the proposed transaction, holders of

Panbela to Host Virtual R&D Day

MINNEAPOLIS, April 27, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, will

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - CDK, PBLA, SJI, OBNK, ZWS

NEW YORK, April 7, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties

PANBELA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela

Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results

Earnings, Press Releases

MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today provides a business

Panbela to Participate in a Panel Discussion: "Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology," at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET

MINNEAPOLIS, March 23, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer,

Panbela to Participate in the 34th Annual Roth Conference

MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer,

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates MTOR, TEN, DWIN, PBLA

NEW YORK, Feb. 28, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties

Lifshitz Law PLLC Announces Investigation of APR, EXTN, MCAE, and PBLA

News, Legal, Press Releases

NEW YORK, Feb. 26, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (NASDAQ:APR) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of APR to Owens & Minor, Inc.

PANBELA THERAPEUTICS INVESTOR ALERT By The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates HMHC, TGNA, MTOR, PBLA

Legal, Press Releases

NEW YORK, NY / ACCESSWIRE / February 23, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary

Lifshitz Law PLLC Announces Investigation of EXTN, MTOR, PBLA, and ECOL

Legal, Press Releases

NEW YORK, NY / ACCESWIRE / February 23, 2022 /Exterran Corporation (NYSE:EXTN)Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of EXTN to Enerflex Ltd.If you

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates HMHC, TGNA, MTOR, PBLA

NEW YORK, Feb. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties

PBLA Stock Investigation: Halper Sadeh LLP Is Investigating Whether the Merger of Panbela Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Panbela Therapeutics, Inc. (NASDAQ:PBLA) and Cancer Prevention Pharmaceuticals, Inc. is fair to Panbela shareholders. Halper Sadeh